Reperfusion Strategy in STEMI: Fibrinolysis When the Cath Lab Is Two Hours Away
A 76-year-old woman with an anterior STEMI, roughly two hours by ground from the nearest catheterization lab and no functioning helicopter. The question isn't whether she needs reperfusion — it's whether a half-dose fibrinolytic beats waiting on a transfer nobody can actually guarantee will arrive on time.
E.H., a 76-year-old woman, was walking her dog along the gravel road behind her house just after eight this morning when a band of pressure closed across her chest and dropped her to one knee. A neighbor out for his own walk found her sitting in the road, unable to catch her breath, and called 911 within minutes. She has been treated for hypertension and high cholesterol for over a decade — hydrochlorothiazide, atorvastatin, nothing more dramatic than that — and has never smoked. Retired eleven years from teaching high school chemistry, she still tutors two afternoons a week at the library in town, a town whose hospital, like most in this stretch of the county, doesn't have a catheterization lab.
EMS reached her at 08:35, about twenty minutes after the first call, and the prehospital ECG they transmitted from the scene showed anterior ST-elevation — a finding that, transmitted before she ever reached a hospital door, effectively set the clock the rest of the morning would be measured against. By the time the emergency physician confirmed the diagnosis and activated the transfer protocol, the storm system that had been building over the county all night had grounded the regional flight program entirely. The nearest catheterization lab is seventy miles away; ground transport at this hour, on these roads, was estimated at roughly ninety-five minutes each way, before accounting for handoff or door-to-balloon time on arrival. Run the arithmetic honestly from her first medical contact and the anticipated delay to a wire crossing her occluded vessel comes to roughly three hours ten minutes — not a marginal miss of the guideline's 120-minute ceiling for preferring pharmacologic reperfusion over transfer, but a delay more than an hour past it. The question the team now has to answer isn't whether she needs reperfusion. It's whether a 76-year-old woman with an anterior STEMI should receive a fibrinolytic drug whose intracranial hemorrhage risk is disproportionately concentrated in patients her age — and if so, at what dose.
In the emergency department, deciding against the clock
Start the clock from her actual first medical contact, not from the moment she reaches a hospital with a cath lab, and the guideline math isn't close: field ECG at 08:35, anticipated device time past three hours if we commit to transfer — that's more than an hour beyond the 120-minute ceiling the STEMI guidelines set for preferring pharmacologic reperfusion. She's 76, so this isn't a case where age-adjusted dosing is a nuance we're layering onto a default decision; it's already been solved for us. The STREAM trial ran into exactly this problem with its own oldest enrollees, found the intracranial hemorrhage rate in patients 75 and up on the full weight-based tenecteplase dose unacceptable, and amended its own protocol mid-trial to halve the dose for that age group. That's not an off-label extrapolation on my part — it's the dosing the trial itself adopted once its own data told it to.
The adjunct regimen follows the same logic. CLARITY-TIMI 28 is where the 300 milligram clopidogrel loading dose alongside fibrinolysis was established — and it excluded patients over 75, so we don't have that evidence base for her; 75 milligrams without a load is what's actually been studied at her age. Same story with enoxaparin: ExTRACT-TIMI 25 is where the weight-based dosing came from, and its own protocol drops the initial IV bolus and reduces the maintenance dose past 75, specifically because the full regimen's bleeding cost outweighed its benefit in that group. None of this is novel for her. It's applying decisions that have already been made.
I'm not disputing any of the pharmacology, and I'm not going to pretend the delay isn't real. But halving the dose doesn't zero out the risk, it just moves it. The age-related rise in intracranial hemorrhage with fibrinolysis wasn't unique to the original STREAM dose — it shows up across the fibrinolytic trial literature going back to GUSTO-I — and a hemorrhage in a 76-year-old with anterior involvement isn't a complication she's likely to walk away from the way a younger patient might.
Three hours of ongoing ischemia is a bad outcome. For most patients, it's a recoverable one. I would rather own that delay and get her to a table than sign off on a drug whose failure mode, in exactly her age group, is the one failure mode we can't fix afterward.
I want to push back on treating ninety-five minutes as a number we can actually plan around. That figure came from a dispatcher doing a rough estimate over the phone on a morning we already know has weather bad enough to ground a helicopter. I've watched transfers like this run forty minutes over more times than I can count, and every one of those forty minutes is more time her artery stays closed no matter which way this debate resolves. Waiting to decide until we know for certain the transfer will run long means deciding after the window to treat has already narrowed. Giving the fibrinolytic now doesn't foreclose the transfer — she still goes, and if the vessel doesn't respond, rescue PCI is still on the table wherever she ends up. It just means we're not betting her reperfusion time entirely on a road-conditions estimate none of us can actually guarantee.
Agreed inside twenty minutes of the emergency physician's original page: labetalol to bring her blood pressure under the 180/110 fibrinolytic threshold, then half-dose tenecteplase, chewed aspirin, unloaded clopidogrel, and age-adjusted enoxaparin — the full adjunct regimen, not the fibrinolytic alone. Ground transport was placed on standby the same moment, targeting departure for planned, not emergent, angiography once the vessel's response can be assessed.
Not agreed: how hard to push for that transport once the drug is running.
Reperfusion is confirmed clinically; transport proceeds on the standard timeline for planned, not urgent, angiography.
Rescue PCI becomes the goal the moment transport arrives, regardless of how the original ninety-five-minute estimate held up.
The interventional cardiologist signed off on the regimen without fully signing off on the premise behind it — wanting a second regional transport service quietly held in reserve from the start, not because anyone doubted the pharmacology, but because he wasn't willing to let a road-conditions estimate be the only plan for getting her to a table if it came to that. The pharmacologist saw no pharmacologic reason to escalate a transfer that was already moving, and worried aloud that treating the estimate as unreliable before it had actually run long risked committing resources meant for someone else's emergency. Neither position was overruled; the second call simply wasn't placed yet when the case was handed off.